Therefore, when used together, pNF-H/NF-L and αII-spectrin can serve as promising biomarkers to distinguish PBBI from other insults, to identify systemic insults with or with brain trauma, and to augment clinical monitoring and prognosis of the two conditions. The gene discussed is NEFL; the disease is brain injury.